HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice.

Abstract
Cellular dipeptidyl peptidase IV (DP IV, CD26) and amino-peptidase N (APN, CD13) play regulatory roles in T cell activation and represent potential targets for treatment of inflammatory disorders. We have developed a novel therapeutic strategy, 'peptidase-targeted Immunoregulation' (PETIR™), which simultaneously targets both cellular DP IV and APN via selective binding sites different from the active sites with a single inhibitor. To prove the therapeutic concept of PETIR™ in autoimmunity of the central nervous system (CNS), we evaluated the effect of a single substance, PETIR-001, in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE) in SJL/J mice. Administration of PETIR-001 significantly delayed and decreased clinical signs of active EAE, when given in a therapeutic manner intraperitoneally from day 15 to day 24 after induction of EAE. Both the acute phase and the first relapse of EAE were markedly inhibited. Importantly, a similar therapeutic benefit was obtained after oral administration of PETIR-001 from day 12 to day 21 after disease induction. Our results demonstrate that PETIR-001 exhibits a therapeutic effect on EAE in SJL/J mice. Thus, PETIR™ represents a novel and efficient therapeutic approach for immunotherapy of CNS inflammation.
AuthorsDirk Reinhold, Ute Bank, Dominik Entz, Alexander Goihl, Diana Stoye, Sabine Wrenger, Stefan Brocke, Anja Thielitz, Sofia Stefin, Karsten Nordhoff, Anke Heimburg, Michael Täger, Siegfried Ansorge
JournalBiological chemistry (Biol Chem) Vol. 392 Issue 3 Pg. 233-7 (Mar 2011) ISSN: 1437-4315 [Electronic] Germany
PMID21194377 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dipeptidyl-Peptidase IV Inhibitors
  • Protease Inhibitors
  • DNA
  • CD13 Antigens
Topics
  • Animals
  • CD13 Antigens (antagonists & inhibitors)
  • Cell Line
  • DNA (biosynthesis)
  • Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental (drug therapy, immunology)
  • Humans
  • Lymphocyte Activation (drug effects)
  • Mice
  • Mice, Inbred Strains
  • Protease Inhibitors (therapeutic use)
  • T-Lymphocytes (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: